View Older Stories View More Recent Stories

Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 18, 2019 06:46AM Pfizer (PFE) Reports FDA Approval of Biosimilar, ABRILADA (adalimumab-afzb) for Multiple Inflammatory Conditions
Nov 18, 2019 06:45AM FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
Nov 15, 2019 09:00AM Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals
Nov 12, 2019 12:17PM Mylan (MYL), Pfizer (PFE) Said New Company to Be Named 'Viatris'
Nov 12, 2019 12:15PM Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Nov 12, 2019 12:15PM Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Nov 12, 2019 06:46AM Pfizer (PFE) Reports Results of Phase 3 Study for XELJANZ (tofacitinib) in Juvenile Idiopathic Arthritis
Nov 12, 2019 06:45AM Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Profes
Nov 8, 2019 08:02AM EMD Serono, Pfizer (PFE) Provide Update on Phase III JAVELIN Gastric 100 Trial
Nov 8, 2019 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 28, 2019 02:00PM European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 21, 2019 08:06AM OPKO Health (OPK), Pfizer (PFE) announced Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with GHD met its primary endpoint
Oct 21, 2019 08:00AM OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Oct 14, 2019 06:08AM Pfizer (PFE) Reports Positive Phase 3 Data from Pivotal Study (JADE MONO-1)
Oct 12, 2019 04:45AM Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis
Oct 7, 2019 06:51AM Akcea Therapeutics (AKCA), Pfizer (PFE) Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Sep 30, 2019 11:45AM Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
Sep 30, 2019 06:22AM Pfizer (PFE) Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI, MEKTOVI and Cetuximab for Treatment of BRAFV600E-mCRC
Sep 30, 2019 02:30AM Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Ca
Sep 27, 2019 09:00AM Pfizer Inc. Awards “Golden Tickets” to Neutrolis and Mediar Therapeutics
Sep 27, 2019 08:02AM Pfizer (PFE) Announces Ian Read to Retire as Executive Chairman; CEO Dr. Albert Bourla Named Chairman
Sep 27, 2019 08:00AM Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman
Sep 27, 2019 06:46AM Pfizer (PFE) Reports Positive Top-Line Results from Second Pivotal Phase 3 Study of Abrocitinib in Patients Aged 12 and Older with Moderate to Severe AD
Sep 27, 2019 06:45AM Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatiti
Sep 27, 2019 02:00AM New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 24, 2019 10:19AM Pfizer Declares Fourth-Quarter 2019 Dividend
Sep 24, 2019 08:03AM Pfizer (PFE) Presents New Evidence of IBRANCE Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients
Sep 24, 2019 08:00AM Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019
Sep 20, 2019 08:11AM Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC
Sep 20, 2019 08:10AM CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Sep 19, 2019 07:40AM Pfizer (PFE) Presents Scientific Advancements in Cancer Care at ESMO
Sep 19, 2019 07:38AM Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio
Sep 9, 2019 08:01AM Pfizer (PFE) Announces Prelim. Results from Proof-of-Concept Phase 2 Study of 20-Valent Pneumococcal Conjugate Vaccine Candidate
Sep 9, 2019 08:00AM Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasi
Aug 21, 2019 10:00AM Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina
Aug 2, 2019 06:49PM Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis
Aug 1, 2019 12:15AM Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company
Jul 30, 2019 08:17AM Pfizer (PFE) Completes Acquisition of Array Biopharma (ARRY)
Jul 30, 2019 08:16AM Pfizer Completes Acquisition of Array Biopharma
Jul 29, 2019 06:46AM Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
Jul 29, 2019 06:45AM Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine
Jul 29, 2019 06:45AM Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Jul 23, 2019 01:50PM Pfizer (PFE) Reports FDA Approval of RUXIENCE (rituximab-pvvr), a Biosimilar for Certain Cancers and Autoimmune Conditions
Jul 23, 2019 01:48PM FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions
Jul 17, 2019 06:00AM Hong Kong Sports and Leisure Expo opens today
Jul 8, 2019 05:50AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy
Jul 5, 2019 11:15PM Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
View More Recent Stories View Older Stories